SCHEMBL5961348

SCHEMBL5961348

Cc1ccc(C(=O)Nc2ccc(Cc3nc(Cl)[c]c(N(C)CC(=O)NC4CCCC4)n3)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 5/20 0.43
HDAC6 Q9UBN7 5/20 0.43
HDAC3 O15379 1/20 0.43
HDAC2 Q92769 1/20 0.43
NCOR2 Q9Y618 1/20 0.43
HPGD P15428 2/20 0.40
KMT2A Q03164 2/20 0.40
GAA P10253 1/20 0.39
TBXA2R P21731 1/20 0.39
PTGDR Q13258 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
ADORA1 P30542 1/20 0.38
EPHX1 P07099 1/20 0.38
MEN1 O00255 1/20 0.38
ACKR3 P25106 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6017031 0.94 GAA (0.42) HDAC1HDAC6GAATBXA2RPTGDR
SCHEMBL5961338 0.93 TBXA2R (0.40) HDAC1HDAC6HPGDKMT2ATBXA2R
SCHEMBL6016975 0.91 EPHX2 (0.43) HPGDKMT2AGAANPC1RAB9A
SCHEMBL6016947 0.89 KMT2A (0.41) KMT2APTGDR2NPC1RAB9ASMN1; SMN2
SCHEMBL5961345 0.88 ACKR3 (0.42) HDAC1HDAC6KMT2APTGDR2NPC1
SCHEMBL5961320 0.86 EPHX1 (0.41) HPGDKMT2AGAANPC1RAB9A
SCHEMBL5961317 0.85 EPHX2 (0.41) HPGDKMT2AGAANPC1RAB9A
SCHEMBL6016971 0.84 HDAC1 (0.44) HDAC1HDAC6HDAC3HDAC2NCOR2
SCHEMBL6016869 0.83 GAA (0.40) HDAC1HDAC6HPGDKMT2AGAA
SCHEMBL5961329 0.83 RAB9A (0.46) KMT2ANPC1RAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006524645-A 2006-11-02 JP claimed
EP-1633726-A1 PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 Actimis Pharmaceuticals, Inc., (US) 2006-03-15 EP claimed
WO-2004096777-A1 PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 ACTIMIS PHARMACEUTICALS, INC. (US) 2004-11-11 WO claimed
EP-1471057-A1 Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 Bayer HealthCare AG (DE) 2004-10-27 EP claimed
EP-1633726-A1 PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 Actimis Pharmaceuticals, Inc., (US) 2006-03-15 EP disclosed
WO-2004096777-A1 PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 ACTIMIS PHARMACEUTICALS, INC. (US) 2004-11-11 WO disclosed
EP-1471057-A1 Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 Bayer HealthCare AG (DE) 2004-10-27 EP disclosed